Compugen Earnings Conference Call (Q1 2008)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other May 14 Calls Today's Calls

Call Details Compugen Earnings Conference Call (Q1 2008) Wed, May 14, 2008, 10:00 am Eastern Listen to the archived event audio About Compugen (NasdaqGM:CGEN) Compugen, Ltd. engages in the discovery, validation, and commercialization of therapeutic and diagnostic biomarker products for cancer, cardiovascular, and immune-related diseases in North America and Europe. Its products are developed based on computer-based discovery platforms, as well as by analyzing various biological data, such as DNA or RNA sequences, gene expression data, protein network data, and data related to drugs in development and to drugs already being commercialized. The company’s validated discovery platforms include Splice Variant based Therapeutic Proteins, Nucleic-Acid Disease Markers, Protein Disease Markers, Monoclonal Antibody Targets, Nucleic-Acid Preclinical Toxicity Markers, Non-SNP Drug Response Markers, GPCR Therapeutic Peptide Ligands, New Indications, and Disease-Associated Conformation Blocker. Its therapeutic product candidates include CGEN-54, a splice variant of the MCP-1 chemokine for inflammatory conditions and cancer; CGEN-241, a splice variant of the MET receptor; CGEN-34, a splice variant of the peptide ANP for cardiovascular system; CGEN-855, an FPRL1 GPCR peptide agonist that consists anti-inflammatory properties; and CGEN-856 and CGEN-857, which are MAS GPCR peptide agonists that have cardiovascular therapeutic properties. Compugen also focuses on the development of traits in plants through gene discovery, genome remodeling, and advanced classical breeding techniques. The company has collaboration and license agreements with Roche; Siemens Healthcare Diagnostics, Inc.; Ortho-Clinical Diagnostics; Biosite; and Teva Pharmacuetical Industries, Ltd.; Merck & Co.; Teva Pharmaceutical Industries, Ltd.; and Medarex, Inc. Compugen was founded in 1993 and is headquartered in Tel Aviv, Israel. More Info: Quote | Chart | News | Profile | Reports | Msgs | Financials